Skip to main content
ARTV
NASDAQ Life Sciences

RA Capital Increases Stake with $11.1M Stock Purchases, Now Owns 36.6% of Artiva Biotherapeutics

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$9.37
Mkt Cap
$226.899M
52W Low
$1.47
52W High
$14.53
52W Position info
537% above low
Off High info
36% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

ARTV has more than doubled off its 52-week low of $1.47.

Summary

RA Capital Management, a major institutional investor with board representation, reported additional open market purchases of Artiva Biotherapeutics common stock totaling $11.1 million, increasing its beneficial ownership to 36.6%.


Key Events · Ownership and Investor Activity · ARTV

  • Major Shareholder Accumulation

    RA Capital Management, L.P. and its affiliates purchased an additional 1,434,155 shares of common stock through open market transactions.

  • Significant Investment

    The purchases, made between June 9 and June 15, 2026, totaled approximately $11.1 million.

  • Increased Ownership Stake

    RA Capital's beneficial ownership in Artiva Biotherapeutics, Inc. now stands at 17,811,623 shares, representing 36.6% of the company's outstanding common stock.

  • Ongoing Institutional Support

    This filing continues a pattern of significant accumulation by major institutional investors, including RA Capital and GC Corp., as seen in recent filings.


Analysis · ARTV · Life Sciences

This Schedule 13D/A reports significant additional open market purchases by RA Capital Management, a major institutional investor with board representation. The $11.1 million in new purchases, following a recent $300 million public offering and positive clinical data, represents a strong vote of confidence in Artiva Biotherapeutics' prospects. RA Capital's increased stake to 36.6% reinforces the ongoing pattern of institutional accumulation, suggesting deep conviction in the company's long-term value.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARTV was trading at $9.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.9M. The 52-week trading range was $1.47 to $14.53. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARTV - Latest Insights

ARTV
Nov 09, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.22
Real-time Price: $3.82 info
Change: -$0.400 (-9%) info
Market Cap: $186.854M info
ARTV
Oct 27, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.09
Real-time Price: $3.82 info
Change: -$0.270 (-7%) info
Market Cap: $186.854M info
ARTV
Oct 27, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
10
Price at Filing: $6.30
Real-time Price: $3.82 info
Change: -$2.48 (-39%) info
Market Cap: $186.854M info
ARTV
Oct 01, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $3.82 info
Change: -$3.43 (-47%) info
Market Cap: $186.854M info
ARTV
Aug 06, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.58
Real-time Price: $3.82 info
Change: -$7.76 (-67%) info
Market Cap: $186.854M info